Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Multiple Sclerosis Relapse”

1,002 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 1,002 results

Large-scale testing (Phase 3)Study completedNCT01201356
What this trial is testing

Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis

Who this might be right for
Relapsing Forms of Multiple Sclerosis
Novartis Pharmaceuticals 4,125
Large-scale testing (Phase 3)Ended earlyNCT01047319
What this trial is testing

Evaluate the Long-term Safety, Tolerability and Effect of Daily Oral Laquinimod 0.6 mg on Disease Course in Subjects With Relapsing Multiple Sclerosis

Who this might be right for
Relapsing Multiple Sclerosis
Teva Branded Pharmaceutical Products R&D, Inc. 1,047
Large-scale testing (Phase 3)Study completedNCT01707992
What this trial is testing

The Efficacy, Safety, and Tolerability of Laquinimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)

Who this might be right for
Multiple Sclerosis
Teva Branded Pharmaceutical Products R&D, Inc. 2,199
Testing effectiveness (Phase 2)Study completedNCT00228163
What this trial is testing

Long Term Safety and Efficacy of Teriflunomide (HMR1726) in Multiple Sclerosis With Relapses

Who this might be right for
Multiple Sclerosis
Sanofi 147
Large-scale testing (Phase 3)Study completedNCT00619307
What this trial is testing

Transition to Rebif New Formulation

Who this might be right for
Relapsing Multiple Sclerosis
Merck KGaA, Darmstadt, Germany 117
Large-scale testing (Phase 3)Study completedNCT00027300
What this trial is testing

Safety and Efficacy of Natalizumab in the Treatment of Multiple Sclerosis

Who this might be right for
Multiple Sclerosis, Relapsing-Remitting
Biogen 900
Post-approval studies (Phase 4)Study completedNCT05199571
What this trial is testing

Study of Efficacy and Safety of Ofatumumab in Relapsing Multiple Sclerosis (RMS) Patients in China

Who this might be right for
Relapsing Multiple Sclerosis
Novartis Pharmaceuticals 99
Large-scale testing (Phase 3)Study completedNCT03774407
What this trial is testing

Vaginal Estriol in Multiple Sclerosis

Who this might be right for
Multiple SclerosisNeurogenic Bladder
Texas Tech University Health Sciences Center 21
Large-scale testing (Phase 3)Study completedNCT04626921
What this trial is testing

A Multi-Center, Open-Label Long-Term Extension Study of CNM-Au8 In Patients With Stable Relapsing Multiple Sclerosis

Who this might be right for
Relapsing Multiple Sclerosis
Clene Nanomedicine 55
Testing effectiveness (Phase 2)UnknownNCT01466114
What this trial is testing

Estriol Treatment in Multiple Sclerosis (MS): Effect on Cognition

Who this might be right for
Relapsing-remitting Multiple SclerosisSecondary-progressive Multiple SclerosisPrimary-progressive Multiple Sclerosis
University of California, Los Angeles 64
Not applicableLooking for participantsNCT06143514
What this trial is testing

A Study Evaluating the Presence and Concentration of BRIUMVI™ (Ublituximab) in Breast Milk

Who this might be right for
Relapsing Multiple Sclerosis
TG Therapeutics, Inc. 16
Post-approval studies (Phase 4)Study completedNCT02048072
What this trial is testing

Evaluation of the Autonomic Nervous System During First-dosing With 0.5mg of Fingolimod (Gilenya) in Patients With Relapsing-remitting MS

Who this might be right for
Multiple SclerosisAutonomic Nervous System Dysfunction
Jochen Vehoff 33
Testing effectiveness (Phase 2)Ended earlyNCT04767698
What this trial is testing

Addition of Belimumab to B-cell Depletion in Relapsing-remitting Multiple Sclerosis

Who this might be right for
Multiple Sclerosis
Johns Hopkins University 4
Post-approval studies (Phase 4)Study completedNCT03853746
What this trial is testing

Short-term B-cell Depletion in Relapsing Multiple Sclerosis

Who this might be right for
Multiple Sclerosis
Johns Hopkins University 10
Not applicableStudy completedNCT00787657
What this trial is testing

Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment

Who this might be right for
Relapsing Remitting Multiple Sclerosis (RRMS)
Bayer 1,723
Large-scale testing (Phase 3)Study completedNCT00134563
What this trial is testing

Study of Teriflunomide in Reducing the Frequency of Relapses and Accumulation of Disability in Patients With Multiple Sclerosis

Who this might be right for
Multiple Sclerosis
Sanofi 1,088
Testing effectiveness (Phase 2)Study completedNCT00882999
What this trial is testing

Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)

Who this might be right for
Relapsing-Remitting Multiple Sclerosis
Eli Lilly and Company 245
Not applicableStudy completedNCT05366036
What this trial is testing

Tecfidera (Dimethyl Fumarate) Capsules in Korean Participants With Relapsing-Remitting Multiple Sclerosis

Who this might be right for
Multiple Sclerosis, Relapsing-remitting
Eisai Korea Inc. 172
Not applicableLooking for participantsNCT06455332
What this trial is testing

Predictive Value of the Optic Nerve Involvement in Clinically Isolated Syndrome

Who this might be right for
Clinically Isolated SyndromeMultiple Sclerosis
University Hospital, Lille 200
Testing effectiveness (Phase 2)Study completedNCT02782858
What this trial is testing

Clinical Trial Assessing the HERV-W Env Antagonist GNbAC1 for Efficacy in MS

Who this might be right for
Multiple Sclerosis, Relapsing-Remitting
GeNeuro SA 270
Load More Results